Long-term damage assessment in patients with microscopic polyangiitis and renal-limited vasculitis using the Vasculitis Damage Index

Modern Rheumatology

Volumn 24, Issue 1, 2014, Pages 112-119

  Itabashi, Mitsuyo ^a   Takei, Takashi ^a   Moriyama, Takahito ^a   Shiohira, Syunji ^a   Shimizu, Ari ^a   Tsuruta, Yuki ^a   Uchida, Keiko ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Microscopic polyangiitis; Relapse; Renal limited vasculitis; Steroid; Vasculitis Damage Index

Indexed keywords

ADULT; AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CORRELATIONAL STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; EYE INJURY; FEMALE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MALE; MICROSCOPIC POLYANGIITIS; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL; RELAPSE; RENAL LIMITED VASCULITIS; RETROSPECTIVE STUDY; VASCULITIS; VASCULITIS DAMAGE INDEX;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KIDNEY; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VASCULITIS;

EID: 84905017668     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.852836     Document Type: Article

References (23)

1. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet. 2006;368:404-18.
2. Chen M, Kallenberg CG. ANCA-Associated vasculitides- advances in pathogenesis and treatment. Nat Rev Rheumatol. 2010;6:653-64.
3. Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford). 2002;41:481-3.
4. Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K, et al. Incidence of ANCA-Associated primary renal vasculitis in Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol. 2006;1:1016-22.
5. Watts RA, Scott DG, Jayne DRW, Ito-Ihara T, Muso E, Fujimoto S, et al. Renal vasculitis in Japan and UK-Are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant. 2008;23:3743-5.
6. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44.
7. Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63:1307-11.
8. Itabashi M, Takei T, Yabuki Y, Suzuk Hi, Ando M, Akamatsu M, et al. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-Associated vasculitis in Japan. Nephron Clin Pract. 2010;115:c21-c27.
9. Itabashi M, Takei T, Morito T, Yabuki Y, Suzuki H, Ando M, et al. Estimation of BVAS in patients with microscopic polyangiitis in Japan. Clin Rheumatol. 2011;30(11):1499-505.
10. Exley AR, Bacon PA, Luqmani RA. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitide. Arthritis Rheum. 1997;40:371-80.
11. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005;52:2168-78.
12. Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-Associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22:394-404.
13. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 1994;37: 187-92.
14. Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283-92.
15. Mukhtyar CB, Flossmann O, Luqmani RA. Clinical and biological assessment in systemic necrotizing vasculitides. Clin Exp Rheumatol. 2006;24:S92-9.
16. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114:463-9.
17. Suppiah R, Flossman O, Mukhtyar C, Alberici F, Baslund B, Brown D, et al. Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann Rheum Dis. 2011;70:80-5.
18. Seo P, Luqmani RA, Flossmann O, Hellmich B, Herlyn K, Hoffman GS, et al. The future of damage assessment in vasculitis. J Rheumatol. 2007;34:1357-71.
19. Mohammad AJ, Bakoush O, Sturfelt G. The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI). Scand J Rheumatol. 2009;38: 268-75.
20. Kamali S, Erer B, Artim-Esen B, Gul A, Ocal L, Konice M, et al. Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients. J Rheumatol. 2010;37: 374-8.
21. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology. 2002;41: 572-81.
22. Exley AR, Carruthers DM, Luqmani RA, Kitas GD, Gordon C, Janssen BA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM. 1997;90:391-9.
23. Brijker F, Magee CC, Tervaert JW, O'Neill S, Walshe JJ. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies. Clin Nephrol. 1999;52:344-51.